Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−13.59 USD
−209.42 M USD
263.00 M USD
18.44 M
About MORPHOSYS AG
Sector
Industry
CEO
Arkadius Pichota
Website
Headquarters
Planegg
Founded
1992
ISIN
DE0006632003
FIGI
BBG000RP34K0
MorphoSys AG is a biopharmaceutical company, which engages in the development and commercialization of cancer therapeutics. Its clinical programs focus on Pelabresib and Tulmimetostat. The company was founded by Andreas Pluckthun and Simon E. Moroney in July 1992 and is headquartered in Planegg, Germany.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of MPSYF is 73.27 USD — it has increased by 2.10% in the past 24 hours. Watch MorphoSys AG stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on OTC exchange MorphoSys AG stocks are traded under the ticker MPSYF.
MPSYF reached its all-time high on Jul 23, 2018 with the price of 142.85 USD, and its all-time low was 13.84 USD and was reached on Dec 16, 2022. View more price dynamics on MPSYF chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
MPSYF stock is 2.06% volatile and has beta coefficient of −0.11. Track MorphoSys AG stock price on the chart and check out the list of the most volatile stocks — is MorphoSys AG there?
Today MorphoSys AG has the market capitalization of 2.69 B, it has increased by 0.74% over the last week.
Yes, you can track MorphoSys AG financials in yearly and quarterly reports right on TradingView.
MorphoSys AG is going to release the next earnings report on Nov 18, 2024. Keep track of upcoming events with our Earnings Calendar.
MPSYF net income for the last quarter is −84.83 M USD, while the quarter before that showed −339.84 M USD of net income which accounts for 75.04% change. Track more MorphoSys AG financial stats to get the full picture.
No, MPSYF doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 17, 2024, the company has 564.00 employees. See our rating of the largest employees — is MorphoSys AG on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. MorphoSys AG EBITDA is −464.63 M USD, and current EBITDA margin is −95.29%. See more stats in MorphoSys AG financial statements.
Like other stocks, MPSYF shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade MorphoSys AG stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So MorphoSys AG technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating MorphoSys AG stock shows the buy signal. See more of MorphoSys AG technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.